Royalty Pharma plc Class A Ordinary Shares (RPRX) is a publicly traded Healthcare sector company. As of July 13, 2026, RPRX trades at $56.39 with a market cap of $25.01B and a P/E ratio of 29.54. RPRX moved -0.08% today. Year to date, RPRX is +44.73%; over the trailing twelve months it is +56.23%. Its 52-week range spans $24.05 to $58.84. Analyst consensus is strong buy with an average price target of $59.00. Rallies surfaces RPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for RPRX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $56.39 |
| Market Cap | $25.01B |
| P/E Ratio | 29.54 |
| EPS | $1.91 |
| Dividend Yield | 0.23% |
| 52-Week High | $58.84 |
| 52-Week Low | $24.05 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.44B |
| Net Income | $1.36B |
| Gross Margin | 0.00% |
7 analysts cover RPRX: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $59.00.